According to a research report published earlier today, Goldman Sachs has increased Medicis Pharmaceuticals' MRX PT from $38 to $41.
Goldman Sachs said in the report, “Guidance for 2012, near-term ASP guidance for Solodyn and Ziana, and greater color on the Zyclara strategy left us feeling more comfortable with both the 2012 outlook and the company's longer-term growth strategy. Going forward, the key areas of focus will be understanding the Rx Assist initiative and greater clarity on the growing pipeline. We maintain our Neutral rating, but we have increased our price target.”
Medicis Pharmaceuticals is currently trading at $35.60.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in